News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Notices Sent To Ranbaxy Laboratories (RANBAXY.BO), Cipla Ltd. For Overcharging


12/10/2013 7:48:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cipla Ltd and Ranbaxy Laboratories Ltd have been issued preliminary notices, under the Drugs (Price) Control Order 2013, by the government for overcharging consumers for medicines, a government source told Cogencis on Friday. The government has issued 87 such preliminary notices to various drug makers for overcharging, the source added. The new drug pricing policy recommends market-based pricing, allowing manufacturers to sell medicines at an average price of all brands that have more than 1% market share in a segment. The average price would act as a ceiling price for that particular drug.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES